First-Line Treatment with Nilotinib in Chronic Myeloid Leukemia Patients in Real-Life: Results of the Observational Study Gimema CML0912

INTRODUCTION. Three tyrosine-kinase inhibitors (TKIs, imatinib, nilotinib [NIL] and dasatinib) are approved for first-line treatment of CP CML. Clinical trials, with stringent inclusion/exclusion criteria and management, may be not fully representative of the daily clinical practice. Thus, it is important to retrieve information on the safety and efficacy of TKIs in the real-life setting. Observational studies are particularly useful for these evaluations.